INDEMNIFICATION AGREEMENTIndemnification Agreement • November 20th, 2007 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Agreement made and entered into this ____ day of ______, (the “Agreement”), by and between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company,” which term shall include, where appropriate, any Entity (as hereinafter defined) controlled directly or indirectly by the Company) and ____________ (the “Indemnitee”):
RESTRICTED STOCK PURCHASE AGREEMENTRestricted Stock Purchase Agreement • November 20th, 2007 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
THIS RESTRICTED STOCK PURCHASE AGREEMENT (this “Agreement”) is entered into as of the 4th day of April, 2006, by and between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), and Dr. Antonio M. Gotto, Jr., M.D., D.Phil (the “Equity Participant”).
EMPLOYMENT AGREEMENTEmployment Agreement • November 20th, 2007 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
This EMPLOYMENT AGREEMENT (this “Agreement”) is dated as of the 1st day of July, 2005, by and between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Gerald Wisler (the “Executive”).
UNIVERSITY of PENNSYLVANIA PATENT LICENSE AGREEMENTPatent License Agreement • November 20th, 2007 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • Pennsylvania
This Patent License Agreement (this “Agreement”) is between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), and Aegerion Pharmaceuticals, Inc, a Delaware corporation (“Company”). This Agreement is effective on May 19, 2006 (the “Effective Date”).
AMENDED AND RESTATED CONSULTING AGREEMENTConsulting Agreement • November 20th, 2007 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • Connecticut
THIS AMENDED AND RESTATED CONSULTING AGREEMENT (this “Agreement”) is dated as of the first day of August 2006, by and between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Scheer & Company, Inc., a Connecticut corporation (“Consultant”). The parties entered into the prior Consulting Agreement on July 1, 2005, and the parties now wish to amend and restate that agreement as provided below.
LOAN AND SECURITY AGREEMENTJoinder Agreement • November 20th, 2007 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • California
THIS LOAN AND SECURITY AGREEMENT is made and dated as of March 20, 2007 and is entered into by and between AEGERION PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), with its chief executive office and principal place of business located at 1140 Route 22 East, Suite 304, Bridgewater, NJ 08807 and HERCULES TECHNOLOGY GROWTH CAPITAL, INC., a Maryland corporation (“Lender”), with its principal place of business located at 400 Hamilton Avenue, Palo Alto, CA 94301.
SUBLEASE AGREEMENTSublease Agreement • November 20th, 2007 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
This lease between GLB 3 LLC, a New Jersey limited liability company (herein Landlord), and Tibbett & Britten Group North America, Inc., a Delaware corporation (herein Tenant), is dated for reference purposes only as of this 28th day of April, 2004.
ContractWarrant Agreement • November 20th, 2007 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AS AMENDED, OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933 ACT AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS.
LICENSE AGREEMENTLicense Agreement • November 20th, 2007 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
This License Agreement (this “Agreement”), dated as of May 31, 2006 (the “Effective Date”), is made by and between Bayer HealthCare AG, a German corporation (“Bayer”), and Aegerion Pharmaceuticals, Inc., a Delaware corporation (“Aegerion”). Bayer and Aegerion are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties.”
CONSULTING AGREEMENTConsulting Agreement • November 20th, 2007 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
THIS CONSULTING AGREEMENT (this “Agreement”) is dated as of the 4th day of, April, 2006, by and between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Antonio M. Gotto, Jr., M.D., D.Phil (“Consultant”).
AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • November 20th, 2007 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT is made as of November 9, 2007 (“Investor Rights Agreement”), by and among Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the Investors listed on Schedule I attached hereto (the “Investors”).
